BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

January 21, 2021

Announcement no. 1

Managers’ transactions

BioPorto has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them. BioPorto has been notified that the transaction is carried out for the purpose of settling tax liabilities arising out of returns on BioPorto shares held as pension scheme assets.

1. Details of the person discharging managerial responsibilities/person closely associated 
a) NameThomas Magnussen
2. Reason for the notification 
a) Position/statusChairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendmentInitial notification
3. Details of the issuer 
a) NameBioPorto A/S
b) LEI5299004SWFL5JAN4W830
4. Details of the transaction(s) 
a) Description of the financial instrument, type



of instrument







Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transactionShare sale
c) Price(s) and volume(s)Price: DKK 6.14, Volume: 40,000
d) Aggregated information



  • Aggregated volume



  • Aggregated price
N/A
e) Date of the transaction2021-01-18
f) Place of the transactionNasdaq Copenhagen A/S, XCSE

For further information, please contact:

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment



EN
21/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnost...

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnostisk brug i USA 27. juni, 2025Meddelelse nr. 18 Påbegyndelse af kommercialisering af ProNephro AKITM (NGAL) til diagnostisk brug i USA KØBENHAVN, DANMARK og BOSTON, MA, USA, 27. juni 2025 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) meddelte i dag, at de har påbegyndt kommercialisering i USA af ProNephro AKITM (NGAL) til klinisk anvendelse i risikostratificering af moderat til svær AKI for patienter i alderen 3 måneder til 21 år, ved at modtage den første købsordre på ProNephro AKITM (NGAL) til det amerik...

 PRESS RELEASE

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic...

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market...

 PRESS RELEASE

Tildeling af Warrants

Tildeling af Warrants 12. juni 2025Meddelelse nr. 17                                                                          Tildeling af Warrants København, Danmark, den 12. juni 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 3.250.000 warrants til Selskabets Extended Leadership Team. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,39 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i Selskabets...

 PRESS RELEASE

Grant of Warrants

Grant of Warrants 12 June 2025 Announcement no. 17                                                                          Grant of Warrants Copenhagen, Denmark, June 12, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 3,250,000 warrants to the Extended Leadership Team. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.39 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accord...

 PRESS RELEASE

BioPorto A/S annoncerer udnævnelsen af en ny administrerende direktør ...

BioPorto A/S annoncerer udnævnelsen af en ny administrerende direktør som en del af selskabets successionsstrategi 10. juni, 2025Meddelelse nr. 16 BioPorto A/S annoncerer udnævnelsen af en ny administrerende direktør som en del af selskabets successionsstrategi KØBENHAVN, DANMARK og BOSTON, MA, USA, 10. juni, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR) annoncerede i dag udnævnelsen af Carsten Buhl som Chief Executive Officer (CEO) for BioPorto A/S og dets datterselskaber med virkning fra 1. september 2025, som en del af Selskabets successionsstrategi. B...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch